# Vispacabtagene regedleucel

Source: https://onco.cc/drugs/vispacabtagene-regedleucel/  
OnCo record `vispacabtagene-regedleucel` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Vispacabtagene regedleucel is an experimental allogeneic CAR-T cell therapy from Caribou Biosciences, in phase 1 trials for relapsed or refractory B cell non-Hodgkin lymphoma.

## Summary

Vispacabtagene regedleucel (CB-010, vispa-cel) is an allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited) from Caribou Biosciences. An allogeneic anti-CD19 CAR-T cell therapy made with Cas9 chRDNA guides: the TRAC gene is knocked out to remove the T cell receptor, the anti-CD19 CAR is inserted into TRAC, and PD-1 is knocked out, a strategy designed to limit premature CAR-T cell exhaustion. Its furthest stage is phase 1, for relapsed or refractory B cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in one study linked below. Company calls it its lead clinical-stage program; registry NCT04637763 (phase 1) is active, not recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Also known as: CB-010; vispa-cel
- Tags: pipeline; ctgov-ingest
- Code: CB-010
- Modality: Allogeneic CAR-T cell therapy (CRISPR chRDNA genome-edited)
- Mechanism: An allogeneic anti-CD19 CAR-T cell therapy made with Cas9 chRDNA guides: the TRAC gene is knocked out to remove the T cell receptor, the anti-CD19 CAR is inserted into TRAC, and PD-1 is knocked out, a strategy designed to limit premature CAR-T cell exhaustion.

## Sources

- Caribou Biosciences: cariboubio.com: https://www.cariboubio.com/pipeline
- Caribou Biosciences: cariboubio.com: https://www.cariboubio.com/pipeline
- Caribou Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT04637763
- ClinicalTrials.gov: trials of CB-010: https://clinicaltrials.gov/search?intr=CB-010

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [Caribou Biosciences](https://onco.cc/companies/caribou/)
- trials: [CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)](https://onco.cc/trials/nct04637763/)

---
JSON: https://onco.cc/api/v1/entities/vispacabtagene-regedleucel.json